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INTRODUCTION	
  
	
  
The	
   con?nuous	
   rapid	
   evolu?on	
   of	
   influenza	
   H5	
   and	
   H7	
   viruses	
   driven	
   by	
   error-­‐prone	
  
replica?on	
  and	
   increasingly	
  by	
   immune	
  pressure	
  significantly	
   influences	
  the	
  sensi?vity	
  of	
  
available	
   serological	
   assays.	
   As	
   subs?tu?on	
   rates	
   are	
   significantly	
   higher	
   in	
   influenza	
  HA	
  
and	
  NA	
  genes	
  compared	
  with	
  internal	
  genes,	
  retroviral	
  and	
  len?viral	
  pseudotypes	
  bearing	
  
HA	
  and	
  NA	
  envelope	
  glycoproteins	
  devolved	
   from	
  the	
  rest	
  of	
   the	
  virus	
  are	
   ideal	
   tools	
   to	
  
monitor	
  the	
  effects	
  of	
  viral	
  evolu?on	
  on	
  serological	
  outcomes.	
  	
  
	
  
	
  
	
  
	
  
	
  
AIM	
  	
  
	
  
In	
  order	
  to	
  study	
  the	
  func?onal	
  heterosubtypic	
  neutralizing	
  an?body	
  responses	
  in	
  human	
  
popula?ons	
   we	
   have	
   constructed	
   pseudotypes	
   bearing	
   haemagglu?nin	
   from	
   high	
  
pathogenicity	
  (HPAI)	
  H5	
  and	
  H7	
  strains	
  and	
  integrated	
  these	
  as	
  serological	
  an?gens	
  into	
  a	
  
mul?plex	
   neutraliza?on	
   assay.	
   The	
   development	
   of	
   a	
   mul?plex	
   pla[orm	
   allowing	
   the	
  
measurement	
  of	
  neutralizing	
  an?bodies	
   against	
   two	
   (in	
   this	
   study)	
  or	
  more	
   viruses	
  with	
  
pandemic	
   poten?al	
   in	
   human	
   sera	
   has	
   considerable	
   ?me,	
   cost	
   and	
   standardiza?on	
  
implica?ons	
  for	
  future	
  serological	
  studies.	
  
	
  
	
  
MATERIALS	
  AND	
  METHODS	
  
	
  
Viruses	
  	
  
	
  
Len?viral	
  pseudotypes	
  with	
  HA	
  glycoproteins	
  derived	
  from	
  the	
  clade	
  1	
  H5N1	
  HPAI	
  virus	
  A/
Viet	
   Nam/1194/04	
   and	
   the	
   HPAI	
   H7N1	
   virus	
   A/chicken/Italy/13474/99	
   have	
   been	
  
described	
  previously	
  (2).	
  	
  
Pseudotype	
  viruses	
  were	
  produced	
  by	
  co-­‐transfec?on	
  of	
  293T/17	
  cells	
  with	
  the	
  respec?ve	
  
HA	
  plasmid,	
   the	
  HIV	
  gag-­‐pol	
  plasmid	
  p8.91	
   (3),	
   and	
  either	
   the	
   reporter	
  plasmid	
  pCSFLW	
  
(expressing	
   firefly	
   luciferase)	
   (4)	
   or	
   pCSRLW	
   (expressing	
   renilla	
   luciferase)	
   (5)	
   using	
  
Fugene-­‐6	
  transfec?on	
  reagent	
  (Roche,	
  UK).	
  	
  
	
  
Sera	
  
	
  
Hyper-­‐immune	
  sheep	
  sera	
  SH454	
  raised	
  against	
  NIBRG-­‐14	
  (H5N1	
  HA),	
  and	
  02/294	
  raised	
  
against	
  A/chicken/Italy/13474/99	
  (H7N1	
  HA)	
  were	
  kindly	
  provided	
  by	
  NIBSC	
  .	
  
68	
   serum	
   samples	
   obtained	
   from	
   the	
   Italian	
   popula?on	
   from	
   1992	
   to	
   2007	
   found	
  
previously	
   to	
   be	
   sero-­‐protected	
   against	
   A/Viet	
  Nam/1194/04	
   as	
   determined	
   by	
   the	
   SRH	
  
assay	
  (6).	
  
	
  
HA	
  pseudotype-­‐based	
  neutralizaAon	
  assay	
  
	
  
Serum	
  samples	
  were	
  heat	
  inac?vated	
  at	
  56˚C	
  for	
  30min,	
  two-­‐fold	
  serially	
  diluted	
  in	
  culture	
  
medium	
  and	
  mixed	
  with	
  pseudotype	
  virus	
  (500,000	
  RLU	
  luciferase	
  input)	
  at	
  a	
  1:1	
  v/v	
  ra?o.	
  	
  
Afer	
  incuba?on	
  at	
  37˚C	
  for	
  1	
  hr,	
  1x104	
  293T/17	
  cells	
  were	
  added	
  to	
  each	
  well	
  of	
  a	
  white	
  
96-­‐well	
  flat-­‐bogomed	
  ?ssue	
  culture	
  plate.	
  Firefly	
  and	
  renilla	
  rela?ve	
  light	
  units	
  (RLU)	
  were	
  
evaluated	
  48	
  hr	
  later	
  by	
  luminometry	
  using	
  the	
  Dual-­‐Glo	
  assay	
  system	
  (Promega,	
  UK).	
  IC50	
  
neutralizing	
  an?body	
  ?tres	
  <	
  1:40	
  are	
  considered	
  nega?ve.	
  
	
  
SRH	
  assays	
  
	
  
Agarose	
  immunoplates	
  were	
  carried	
  out	
  with	
  sheep	
  erythrocytes	
  10%	
  (v/v	
  of	
  assay	
  buffer)	
  
sensi?zed	
   by	
   2000	
   Haemagglu?nin	
   Units	
   (HU)/mL	
   of	
   inac?vated	
   A/Vietnam/1194/2004	
  
(H5N1)	
  whole	
  virus,	
  and	
  with	
  the	
  addi?on	
  of	
  5%	
  of	
  guinea-­‐pig	
  complement.	
  	
  
Before	
   tes?ng,	
   serum	
   samples	
   were	
   heat	
   inac?vated	
   at	
   56˚C	
   for	
   30	
  min.	
   Each	
   test	
   run	
  
included	
   nega?ve	
   and	
   posi?ve	
   samples:	
   hyperimmune	
   sheep	
   an?serum	
   A/Vietnam/
1194/04	
  (07/148	
  provided	
  by	
  NIBSC)	
  was	
  used	
  as	
  a	
  posi?ve	
  control.	
  	
  
The	
   diameters	
   of	
   the	
   haemoly?c	
   areas	
   were	
   measured	
   using	
   a	
   Transidyne	
   Calibra?ng	
  
Viewer	
  (Transidyne	
  General	
  Corpora?on,	
  Ann	
  Arbor,	
  MI).	
  
Haemolysis	
  Area	
  <4	
  mm2	
  was	
  considered	
  nega?ve,	
  between	
  4	
  and	
  25	
  mm2	
  was	
  considered	
  
posi?ve	
  but	
  not	
  protec?ve	
  and	
  >25	
  mm2	
  was	
  considered	
  protec?ve.	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
.	
  	
  
	
  
	
  
CONCLUSIONS	
  	
  
v The	
  mul?plex	
  assay	
  described	
  has	
  u?lity	
  for	
  the	
  study	
  of	
  heterosubtypic	
  an?body	
  
responses	
  against	
  Group	
  1	
  and	
  Group	
  2	
  influenza	
  viruses	
  in	
  the	
  same	
  serum	
  sample.	
  
v The	
  pseudotype-­‐based	
  mul?plex	
  neutraliza?on	
  assay	
  presented	
  here	
  is	
  both	
  “serum-­‐
sparing”	
  and	
  “an?gen-­‐sparing”	
  and	
  likely	
  to	
  be	
  more	
  readily	
  standardised	
  than	
  assays	
  
using	
  red	
  blood	
  cells.	
  
v This	
  assay	
  has	
  u?lity	
  for	
  sero-­‐prevalence	
  studies	
  and	
  for	
  the	
  pre-­‐clinical	
  evalua?on	
  of	
  
vaccines	
  and	
  an?virals	
  against	
  avian	
  viruses	
  with	
  pandemic	
  poten?al.	
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RESULTS	
  
	
  
Figure	
  1:	
  Cross-­‐reac?vity	
  an?body	
  profiles	
  of	
  SRH	
  posi?ve	
  human	
  
sera	
  against	
  a	
  Group	
  1	
  H5	
  and	
  a	
  Group	
  2	
  H7	
  virus	
  as	
  measured	
  
using	
  pseudotype	
  neutraliza?on	
  assays.	
  An?body	
  response	
  colour	
  
chart	
   showing	
   the	
   IC50	
   neutralizing	
   an?body	
   ?tres	
   of	
   sera	
   that	
  
have	
  an	
  SRH	
  ?tre	
  >	
  25mm2	
  (34	
  in	
  each	
  column)	
  measured	
  against	
  
H5	
  and	
  H7	
  pseudotypes.	
  Individual	
  end-­‐point	
  ?tres	
  (as	
  calculated	
  
using	
  GraphPad).	
  
Figure	
  2:	
  Phylogene?c	
  tree	
  showing	
  the	
  
rela?onship	
  between	
  	
  influenza	
  HA	
  
subtypes	
  	
  H1-­‐H17	
  (MEGA5	
  Sofware)	
  
Figure	
  3:	
  Comparison	
  of	
   SRH	
  assay	
  versus	
  pseudotype	
  
assay.	
   SRH	
  ?tres	
   expressed	
  as	
  diameter	
  of	
   haemolysis	
  
(in	
  mm2	
  )	
  are	
  ploged	
  on	
  the	
  X-­‐axis.	
  SRH	
  ?tres	
  >	
  25	
  mm2	
  
are	
  considered	
  to	
  be	
  sero-­‐protec?ve	
  and	
  this	
  cut-­‐off	
  is	
  
represented	
   on	
   the	
   plot	
   by	
   a	
   ver?cal	
   red	
   doged	
   line.	
  
IC50	
   pseudotype	
   neutraliza?on	
   ?tres	
   expressed	
   as	
   the	
  
reciprocal	
   of	
   the	
   serum	
   dilu?on	
   that	
   results	
   in	
   a	
   50%	
  
inhibi?on	
  of	
  pseudotype	
  virus	
  entry.	
  	
  
PpNT	
   ?tres	
   >	
   1:40	
   are	
   considered	
   to	
   be	
   posi?ve	
   and	
  
this	
   cut-­‐off	
   is	
   represented	
  by	
   a	
   horizontal	
   blue	
  doged	
  
line.	
  
	
  
More	
   specifically,	
   pseudotype	
   based	
   assays	
   have	
   been	
   shown	
   to	
   be	
   efficient	
   for	
   the	
  
measurement	
   of	
   broadly-­‐neutralizing	
   an?bodies	
   directed	
   against	
   the	
   HA2	
   stalk	
   of	
  
influenza	
   making	
   them	
   ideal	
   serological	
   tools	
   for	
   the	
   study	
   of	
   cross-­‐reac?ve	
   responses	
  
against	
  mul?ple	
  influenza	
  subtypes	
  with	
  pandemic	
  poten?al,	
  such	
  as	
  the	
  H5N1	
  and	
  H7N1	
  
used	
  in	
  the	
  current	
  study	
  (1,2).	
  
 
SRH	
  assay	
  has	
  been	
  shown	
  to	
  detect,	
  not	
  only	
  responses	
  against	
  HA,	
  but	
  also	
  non-­‐specific	
  
an?body	
  responses	
  that	
  are	
  likely	
  to	
  have	
  been	
  elicited	
  against	
  internal	
  proteins.	
  
Titers	
  obtained	
  by	
  pp-­‐NT	
  assay	
  reveal	
  its	
  sensi?vity	
  to	
  measure	
  func?onal	
  responses	
  to	
  both	
  
globular	
  head	
  (HA1)	
  and	
  stalk	
  (HA2)	
  of	
  influenza	
  HA.	
  
